Neflamapimod not checked

EIP Pharma Inc · VX-745

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
7 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α)”In the company’s words, NCT07033481 on ClinicalTrials.gov
Tested for
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Main trialPhase 2
“The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.”In the company’s words, NCT07033481 on ClinicalTrials.gov
Other names
VX-745

Other drugs for Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

All 504 drugs for Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Sep 2026 Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
Phase 2Completed 30 Jun 2019 Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Phase 2Completed 30 Jun 2020 Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
Phase 2Terminated 15 Oct 2020 Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Phase 2Completed 29 May 2025 RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase 2Completed 11 Mar 2026 A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase 2Completed 23 Sep 2026 A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Neflamapimod

Following is part of Solo: you see every change to Neflamapimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in